| 所在主题： | |
| 文件名: 2011年基本药物数据统计.pdf | |
| 资料下载链接地址: https://bbs.pinggu.org/a-1087499.html | |
| 附件大小: | |
|
Bigger means cheaper
It took eight months and more than 200 interviews. But on April 2nd America’s Federal Trade Commission (FTC) decided, in a three-to-one vote, to let Express Scripts acquire Medco. The two firms are America’s second-biggest and biggest pharmacy-benefit managers. Eventually, they may change the way Americans take drugs. Despite an intolerably dull title, pharmacy-benefit managers (PBMs) are important. America is the world’s biggest drug market; in 2010 it spent more than $307 billion on prescription medicines. PBMs are the middlemen that manage drug costs for employers and insurers. Together, Express Scripts and Medco will control more than 40% of the market. Express Scripts announced the acquisition in July 2011. Medco was a good company that had had a bad year, and so looked cheap. It had lost about 30% of its business in a few months as some of its largest clients ended their contracts. For both firms, bigger ought to mean better. With scale would come the power to negotiate fatter discounts on drugs, lowering costs for employers and insurers. Pharmacists felt sick when they heard the news. PBMs encourage consumers to fill their prescriptions through the mail instead of going to a costly pharmacy. PBMs, pharmacists fret, will crush their fees for dispensing drugs. Worse, PBMs will demand that drugmakers give them exclusive deals for new, complex medicines. Competitors and consumers will suffer, the pharmacists argue. The FTC disagreed. The merged firm is unlikely to squeeze pharmacies’ fees for dispensing drugs, it ruled. There remain plenty of lively, smaller PBMs. John Kreger of William Blair, an investment bank, says there is enough turmoil—thanks both to the merger and to Express Scripts’ continuing fight with Walgreens, a big pharmacy—that smaller PBMs may snatch new business in the next year. The small fry may also benefit if the pharmacy lobby’s lawsuit against the merger moves forward. The combined firm will have $91 billion in revenue in 2012, estimates Lawrence Marsh, an analyst at Barclays Capital. It is so big that it could shape a new era for America’s drug market. As more drugs lose their patents, consumers will increasingly fill their prescriptions with generics. If Express Scripts has its way, they will also fill their prescriptions by post. Medco recently acquired a firm that compares the efficacy of different drugs. This may prove useful when America begins to see cheap copies of complex drugs, called biosimilars, which will be tested against the originals. The new Express Scripts may also play a role on Barack Obama’s new insurance exchanges, working with insurers to court individuals shopping for health care. Most intriguingly, the new Express Scripts could push Americans to buy the right medicines and take them at the right time. For years PBMs have tested ways to urge consumers to buy cheaper, effective drugs. For example, if a patient wants a branded pill rather than a generic, he must pay for more of it himself. Experiments will probably scale up and become more sophisticated. Eventually, they might even spread to Medicaid, the public programme for the poor. Health reform (unless the Supreme Court strikes it down) will add 16m new members to Medicaid by 2019, a 27% jump. PBMs such as Medco and Express Scripts have so far spent little time chasing the Medicaid market. That may change. 了解Follow Us版 https://bbs.pinggu.org/thread-1130480-1-1.html 英文网址，欢迎补充！ https://bbs.pinggu.org/thread-1410923-1-1.html Follow Us 发帖指南、常见问题及意见征集 https://bbs.pinggu.org/thread-1131076-1-1.html 关于Follow Us 版面建立官方群 https://bbs.pinggu.org/thread-1212960-1-1.html |
|
熟悉论坛请点击新手指南
|
|
| 下载说明 | |
|
1、论坛支持迅雷和网际快车等p2p多线程软件下载，请在上面选择下载通道单击右健下载即可。 2、论坛会定期自动批量更新下载地址,所以请不要浪费时间盗链论坛资源,盗链地址会很快失效。 3、本站为非盈利性质的学术交流网站,鼓励和保护原创作品，拒绝未经版权人许可的上传行为。本站如接到版权人发出的合格侵权通知，将积极的采取必要措施；同时，本站也将在技术手段和能力范围内，履行版权保护的注意义务。 (如有侵权，欢迎举报) |
|
京ICP备16021002号-2 京B2-20170662号
京公网安备 11010802022788号
论坛法律顾问：王进律师
知识产权保护声明
免责及隐私声明
